CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trial

Discovery of the c-Jun N-Terminal Kinase Inhibitor CC-90001

(2021) Mark A. Nagy et al.   JOURNAL OF MEDICINAL CHEMISTRY

Airway epithelial specific deletion of Jun-N-terminal kinase 1 attenuates pulmonary fibrosis in two independent mouse models

(2020) Jos L. van der Velden et al.   PLoS One

Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management

(2019) Marlies Wijsenbeek et al.   CURRENT MEDICAL RESEARCH AND OPINION

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases

(2019) Kevin R. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial

(2019) Toby M Maher et al.   Lancet Respiratory Medicine

CT-Pathologic Correlation of Major Types of Pulmonary Fibrosis: Insights for Revisions to Current Guidelines

(2018) Jonathan H. Chung et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

Idiopathic Pulmonary Fibrosis

(2018) David J. Lederer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper

(2018) David A Lynch et al.   Lancet Respiratory Medicine

Quantitative high-resolution computed tomography fibrosis score: performance characteristics in idiopathic pulmonary fibrosis

(2018) Stephen M. Humphries et al.   EUROPEAN RESPIRATORY JOURNAL

Idiopathic Pulmonary Fibrosis: Data-driven Textural Analysis of Extent of Fibrosis at Baseline and 15-Month Follow-up

(2017) Stephen M. Humphries et al.   RADIOLOGY

Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions

(2017) Jonathan A. Galli et al.   RESPIROLOGY

JNK Signaling: Regulation and Functions Based on Complex Protein-Protein Partnerships

(2016) András Zeke et al.   MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS

Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials

(2015) Paul W. Noble et al.   EUROPEAN RESPIRATORY JOURNAL

A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

(2014) Talmadge E. King et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

(2014) Luca Richeldi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lung fibrotic tenascin-C upregulation is associated with other extracellular matrix proteins and induced by TGFβ1

(2014) Susanna Estany et al.   BMC Pulmonary Medicine

Connective tissue growth factor induces collagen I expression in human lung fibroblasts through the Rac1/MLK3/JNK/AP-1 pathway

(2013) Chien-Huang Lin et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor

(2011) Véronique Plantevin Krenitsky et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Long-term Course and Prognosis of Idiopathic Pulmonary Fibrosis in the New Millennium

(2011) Steven D. Nathan et al.   CHEST

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

(2011) Paul W Noble et al.   LANCET

Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis

(2010) T. Senoo et al.   THORAX

Modulation of Hepatic Fibrosis by c-Jun-N-Terminal Kinase Inhibition

(2009) Johannes Kluwe et al.   GASTROENTEROLOGY

The SF-36 and SGRQ: Validity and first look at minimum important differences in IPF

(2009) Jeffrey J. Swigris et al.   RESPIRATORY MEDICINE

c-Jun N-Terminal Kinase 1 Is Required for the Development of Pulmonary Fibrosis

(2008) John F. Alcorn et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

MMP1 and MMP7 as Potential Peripheral Blood Biomarkers in Idiopathic Pulmonary Fibrosis

(2008) Ivan O Rosas et al.   PLOS MEDICINE